TME Pharma N.V.
https://www.tmepharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TME Pharma N.V.
Chinese Biotechs Raise $743m In Three March IPOs
RemeGen touched down in Shanghai to score a dual listing on top of a 2020 initial public offering in Hong Kong. Meanwhile, domestic HPV vaccine maker Recbio and small molecule-focused Shouyao made their debuts on the Hong Kong and Shanghai markets respectively.
Recbio First Biotech To Brave A Hong Kong IPO In 2022
Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.
China’s Lead mRNA COVID-19 Vaccine Candidate Faces Phase III Delays
The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.
Tech Transfer Roundup: Novo Nordisk Foundation, Broad Institute Team On Genomic Drivers Of Disease
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
-
- NOXXON Pharma AG, NOXXON Pharma NV